Introduction
============

Ductal carcinoma in situ with microinvasion (DCISM) is a rare pathologic entity accounting for \~0.6%--3.4% of all breast cancer cases.[@b1-ott-11-9071],[@b2-ott-11-9071] The specific definitions of this entity have varied in the past decades, and the seventh edition of the American Joint Committee on Cancer *Cancer Staging Manual* defines microinvasion as not exceeding 1 mm in size.[@b3-ott-11-9071] With the widespread use of mammography in screening, increasing numbers of DCISM are now being detected and diagnosed.

The presence of lymph node (LN) metastasis has been reported to range between 0% and 25%.[@b4-ott-11-9071]--[@b9-ott-11-9071] Although many pathological factors might be associated with LN metastasis, including lymph angiogenesis,[@b7-ott-11-9071] high-grade disease,[@b10-ott-11-9071] larger ductal carcinoma in situ (DCIS) lesion,[@b11-ott-11-9071] and younger age,[@b9-ott-11-9071] the reliability of these conclusions should be interpreted carefully due to the small number of studies.

DCISM presents a therapeutic conundrum. The prognosis falls somewhere between invasive cancer and DCIS, but the specific prognosis of individuals is unclear, and risk stratification based on retrospective reports has been difficult due to the overall rarity of this entity.[@b12-ott-11-9071] Although classified as invasive cancer, DCISM has an excellent prognosis compared with DCIS.[@b4-ott-11-9071] Unfortunately, an agreement has not been reached on the standard therapy for DCISM. Adjuvant chemotherapy is generally recommended for invasive ductal carcinoma (IDC) with LN metastasis, while it remains undetermined whether DCISM with LN involvement should receive chemotherapy.

Based on retrieved DCISM data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry database (1998--2013), we designed a population-based study to identify risk factors for LN metastasis in DCISM and, more importantly, weigh the impact of adjuvant chemotherapy on DCISM.

Methods
=======

Patient selection
-----------------

Data were extracted from the National Cancer Institute's SEER program between 1998 and 2013. The SEER project is a United States population-based cancer registry that began in 1973 and now includes 18 registries across the United States, covering \~28% of the American population.

We focused on cases diagnosed between 1998 and 2013 with microscopically confirmed stage T1mic, and we selected patients aged between 20 and 70 years old. Information about patients with infiltrating duct carcinoma (code 8500/3) was referenced to the International Classification of Diseases for Oncology, version 3. Patients who were identified at autopsy, with death certificate only, no surgery treatment, or incomplete survival times were excluded from our study. Tumor demographics included grade (grade I: well differentiated/grade II: moderately differentiated/grade III: poorly differentiated/grade IV: undifferentiated/unknown), hormone status (estrogen receptor \[ER\] positive/negative/unknown, progesterone receptor \[PR\] positive/negative/unknown), and human epidermal growth factor receptor 2 (HER2) status (positive/negative/unknown). Treatment characteristics included surgery (lumpectomy/mastectomy), chemotherapy, and radiotherapy. Additionally, as SEER did not report the type of LN surgery, we used the number of LNs excised as an alternative. We define patients with 1--5 LNs removed as sentinel lymph node biopsy (SLNB) and \>5 LNs removed as axillary lymph node dissection (ALND), as previous studies reported.[@b13-ott-11-9071],[@b14-ott-11-9071] A total of 6,219 female patients with DCISM met our inclusion criteria.

Statistical analysis
--------------------

The characteristics of the two groups of patients (LN positive vs LN negative) were compared using Pearson's chi-squared test or Fisher's exact test. Logistic regression analysis was further used to identify the independent factors associated with LN metastasis. Overall survival (OS) was calculated as the time from the date of diagnosis to the date of death from any cause. Breast cancer-specific survival (BCSS) was measured from the date of diagnosis to the date of death owing to breast cancer. Survival rates were assessed using the Kaplan--Meier method and compared using the log-rank test. Furthermore, we used the Cox proportional hazards model to calculate HR and 95% CI for the prognostic factors of DCISM. To minimize group differences, a 1:1 propensity score matching was used.

All statistical analyses were performed using SPSS statistical software, version 22.0 (IBM Corporation, Armonk, NY, USA), and a *P*-value \<0.05 was considered statistically significant.

Ethics statement
----------------

This was a retrospective analysis using data from the SEER database, which is a public health database. The data released by the SEER database were publicly accessible to applicants and did not require informed patient consent for use.

Results
=======

Patient and treatment characteristics
-------------------------------------

The characteristics of all patients are listed in [Table S1](#SD1-ott-11-9071){ref-type="supplementary-material"}. The mean (range) age at diagnosis of DCISM was 53.8 (20--70) years. Overall, the majority (74.5%) of patients were white. More than half (58.4%) of the patients had low-grade disease (grade I+II). Moreover, 68.7% of patients had positive ER expression, and 55.2% had positive PR expression. Only 7.8% of patients had LN metastasis. As SEER began recording HER2 status in 2010, there was little information available for this subgroup.

For surgical treatment, SLNB was performed in 4,102 patients (66.4%), lumpectomy was performed in 3,388 patients (54.5%), corresponding to 1,496 patients (24.2%) with ALND and 2,831 patients (45.5%) with mastectomy. In addition, 46.9% of patients underwent radiotherapy, and a small number of patients (9.8%) received chemotherapy.

LN positive vs LN negative
--------------------------

We then divided DCISM into two groups: LN positive and LN negative. There was no difference in ER (*P*=0.396), PR (*P*=0.414), and HER2 (*P*=0.126) expression, but much more high-grade diseases and young patients were observed in the LN-positive group (50.9% vs 41.5%, *P*\<0.001; 30.1% vs 17.4%, *P*\<0.001, respectively). Age at diagnosis, ethnicity, grade, hormone receptor status, and HER2 status were analyzed in the binary logistic regression model. Using the multivariate analysis, younger age and higher grade disease were found to be independent risk factors responsible for LN metastasis. The results of the univariate and multivariate analyses are summarized in [Tables 1](#t1-ott-11-9071){ref-type="table"} and [2](#t2-ott-11-9071){ref-type="table"}.

Survival outcomes
-----------------

The median follow-up was 76 months (range, 1--170 months). There were 271 deaths in all and 90 breast cancer-specific deaths. The 10-year OS and BCSS of all patients were 93.8% and 97.7%, respectively. The 10-year OS for LN-negative patients was 94.7%, compared to 87.4% in the LN-positive group ([Figure 1A](#f1-ott-11-9071){ref-type="fig"}; *P*\<0.001), and the 10-year BCSS for LN-negative patients was 98.4%, compared to 91.3% in the LN-positive group ([Figure 1B](#f1-ott-11-9071){ref-type="fig"}; *P*\<0.001).

Prognostic factor
-----------------

In the univariate analysis, age at diagnosis, ethnicity, tumor grade, PR status, LN status, radiotherapy, chemotherapy, and surgery treatment were significantly associated with OS or (and) BCSS.

In the multivariate analysis, older age (HR 1.762, 95% CI 1.228--2.529, *P*=0.002), black women (HR 2.188, 95% CI 1.645--2.910, *P*\<0.001), LN metastasis (N2: HR 3.697, 95% CI 1.818--7.519, *P\<*0.001; N3: HR 6.846, 95% CI 1.989--23.568, *P*=0.002), and chemotherapy (HR 1.701, 95% CI 1.133--2.555, *P*=0.010) were associated with worse OS. However, positive PR expression (HR 0.559, 95% CI 0.385--0.811, *P*=0.002) and radiotherapy (HR 0.597, 95% CI 0.426--0.837, *P*=0.003) were significantly good predictors of breast cancer OS. Moreover, black women (HR 2.081, 95% CI 1.243--3.484, *P*=0.005), LN metastasis (N2: HR 4.732, 95% CI 1.977--11.324, *P\<*0.001; N3: HR 7.139, 95% CI 1.449--35.161, *P*=0.016), chemotherapy (HR 3.938, 95% CI 2.168--7.153, *P\<*0.001), and mastectomy (HR 2.163, 95% CI 1.182--3.956, *P*=0.012) were related with worse BCSS. As the majority of HER2 variables was not known (SEER database collected HER2 information after 2010), the results of HRs were insignificant in the univariate and multivariate analyses. The results of univariate and multivariate analyses are listed in [Table 3](#t3-ott-11-9071){ref-type="table"}.

Propensity score matching
-------------------------

Patients who received chemotherapy may have been subject to some selection bias. To further adjust for potential baseline bias and confounders, propensity score matching was carried out. Moreover, to minimize confounders, we also excluded some unavailable or unknown information, such as unknown ER status, PR status, LN stage, and radiotherapy. Finally, a total of 3,198 patients with complete information were available. All matching variables were balanced between the two groups (chemotherapy vs no chemotherapy); details of the original, unmatched cohort, and propensity-matched cohort are shown in [Table 4](#t4-ott-11-9071){ref-type="table"}. After matching, survival analysis and log-rank testing revealed worse BCSS in the chemotherapy-treated group than in the no chemotherapy group ([Figure 1D](#f1-ott-11-9071){ref-type="fig"}; *P*=0.008), but there was no statistical significance for OS ([Figure 1C](#f1-ott-11-9071){ref-type="fig"}; *P*=0.248).

In the LN-negative subgroup, the same methods were implemented as earlier. Finally, 2,916 LN-negative patients with complete information were available; details of the original, unmatched cohort, and propensity-matched cohort are shown in [Table S2](#SD1-ott-11-9071){ref-type="supplementary-material"}. After matching, survival analysis showed no statistical significance in the two groups (chemotherapy vs no chemotherapy) for OS ([Figure S1A](#SD1-ott-11-9071){ref-type="supplementary-material"}; *P*=0.324) and BCSS ([Figure S1B](#SD1-ott-11-9071){ref-type="supplementary-material"}; *P*=0.121). Unfortunately, due to the limited number, we could not apply propensity score matching to the LN-positive subgroup.

Subgroup analysis
-----------------

Univariate and multivariate Cox proportional hazards regression models were also employed in the LN-negative and LN-positive subgroups. For the LN-negative subgroup, chemotherapy was an independent factor for worse OS (HR 2.119, 95% CI 1.311--3.424, *P*=0.002) and BCSS (HR 4.631, 95% CI 2.253--9.114, *P*\<0.001), as shown in [Table S3](#SD1-ott-11-9071){ref-type="supplementary-material"}. For the LN-positive subgroup, chemotherapy was not associated with better OS (*P*=0.559) and BCSS (*P*=0.288), as shown in [Table S4](#SD1-ott-11-9071){ref-type="supplementary-material"}.

Discussion
==========

DCISM is a disease entity that is not fully characterized, in contrast to DCIS and IDC. The clinical-pathological characteristics are unclear, and the optimal treatment is controversial due to limited information. Although there have already been two studies about DCISM based on the SEER database,[@b15-ott-11-9071],[@b16-ott-11-9071] they focused on comparing DCISM with DCIS and IDC and did not analyze the therapy strategies, such as chemotherapy and surgical options. We first divided the DCISM into two groups (LN positive vs LN negative) to explore the difference between the two groups and identify the potential risks for LN metastasis. To our knowledge, this population-based study is the first to identify predictive markers for LN metastasis and report the potential influence of adjuvant chemotherapy on DCISM.

There is a potential risk of LN metastasis in DCISM. Some studies reported that it was valuable to perform SLNB routinely,[@b9-ott-11-9071] while others had different perspectives and stated that SLNB should be individualized.[@b17-ott-11-9071] These debates raised the question of whether there were subgroups of patients who were at high risk of LN metastasis.

In our study, 7.8% of patients had LN metastasis. Importantly, our study identified that younger age and higher grade disease were risk factors for LN involvement. In a study of 81 patients with DCISM, Gray et al suggested that extensive size of DCIS (\>5 cm) and multifocal microinvasion were associated with LN metastasis.[@b5-ott-11-9071] Wasserberg et al revealed that nuclear grade, comedonecrosis, and DCIS-involved ducts might predict LN metastasis. However, only high-grade status was a significant factor for LN metastasis in T1a breast cancer.[@b10-ott-11-9071] Kapoor et al analyzed 45 patients with DCISM and found that the LN was involved in nine patients. In the multivariate analysis, only negative ER status (*P*\<0.02) was a risk factor for LN metastasis rather than high-grade disease, comedonecrosis, lymphovascular invasion, DCIS size, multifocal microinvasion, and HER2 status.[@b18-ott-11-9071] However, several studies have proposed contrary conclusions. Guth et al proposed that comedonecrosis, nuclear grade, multifocal DCIS, and hormone receptor status might not predict LN involvement, but patients with LN positivity tended to be younger,[@b9-ott-11-9071] which is consistent with our current study. Pimiento et al studied the correlation between clinical-pathological features and axillary LN metastasis in 90 female patients with DCISM. Unfortunately, this study failed to identify any significant predictive factor.[@b19-ott-11-9071] In addition, by studying records from a prospective institutional database, Matsen et al investigated 414 patients with DCISM and suggested that multifocal microinvasion may not be correlated with LN involvement.[@b12-ott-11-9071] All these published studies were limited by small sample size, and the reliability of their conclusions is therefore not confirmed. Larger studies are urgently needed to identify the relevant predictive factors of LN metastasis in patients with DCISM.

To take it further, the significance of LN involvement in DCISM is another topic of interest -- specifically, the predictive value of LN involvement on locoregional recurrence and distant metastasis. Unfortunately, the SEER database cannot provide this critical information.

The other interesting finding from our current study is that adjuvant chemotherapy might not be necessary for DCISM. Especially for the subgroup of LN-negative patients, chemotherapy is even a risk prognostic factor for worse OS (HR 2.119, 95% CI 1.311--3.424, *P*=0.002) and BCSS (HR 4.631, 95% CI 2.253--9.114, *P*\<0.001). Although, we could not apply propensity score matching to investigate the effect of chemotherapy in the LN-positive subgroup (it may be underpowered to do so), univariate and multivariate Cox proportional hazards regression models suggested that chemotherapy was not associated with better OS (*P*=0.559) and BCSS (*P*=0.288).

Because chemotherapy is seldom needed for DCISM, the impact of chemotherapy on this uncommon entity is unclear until now. Fang et al presented 84 DCISM patients, 16 of whom were treated with chemotherapy and trastuzumab. After univariate and multivariate analyses, HER2 status was an independent predictor for worse disease-free survival with a median follow-up of 31 months, and they suggested that chemotherapy and target therapy in patients with HER2-positive disease seemed to be reasonable.[@b20-ott-11-9071] Matsen et al reported that patients with LN involvement and multifocal microinvasion were more likely to receive chemotherapy.[@b12-ott-11-9071] Lyons et al found 14 patients with positive sentinel LN (SLN) among 112 patients with DCISM, and adjuvant chemotherapy was given to all patients with macrometastasis. With a median follow-up of 6 years, there were five local recurrences. It is worth discussing that all five recurrences were observed in patients with negative SLNs. Thus, the authors concluded that DCISM patients with SLN macrometastasis would benefit from adjuvant chemotherapy.[@b21-ott-11-9071] On the other hand, regardless of LN metastasis, DCISM patients also reported excellent prognosis.[@b22-ott-11-9071],[@b23-ott-11-9071] Therefore, adjuvant therapy may be unnecessary for this already excellent prognosis disease.[@b24-ott-11-9071] Niu et al found no statistical significance in the 5-year disease-free survival or OS between chemotherapy and non-chemotherapy groups but it might improve the outcomes of ER-negative/PR-negative DCISM patients.[@b25-ott-11-9071] According to the latest guidelines, including National Comprehensive Cancer Network guidelines, chemotherapy was routinely recommended for breast cancer patients with LN involvement.[@b26-ott-11-9071] However, it is unclear whether patients were potentially over-treated or the relatively rare recurrence in the node-positive group was due to adjuvant chemotherapy.[@b27-ott-11-9071] The MINDACT trial is a phase III trial comparing the 70-gene signature with the commonly used clinicopathologic criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0--3 positive nodes. It is worth noting that early results from the MINDACT trial suggest that the 70-gene signature can help avoid chemotherapy in certain patients regardless of larger tumor size and nodal status, without compromising the outcome.[@b28-ott-11-9071] Based on these data, in the era of precision medicine, clinicians should consider the biology of tumors while making clinical decisions. The costs and benefits of chemotherapy should be exactly weighted in DCISM patients. In addition, patients who can derive the most benefit from chemotherapy should be further identified.

Our present study has several limitations. First, when both in situ and invasive components are present in a tumor, the SEER database records only the characteristics of the invasive component; therefore, we cannot analyze the impacts of DCIS lesions on LN metastasis. In addition, potentially significant clinicopathological factors, such as vascular invasion, surgical margin status, adjuvant endocrine therapy, and targeted therapy, are not provided by the SEER database. Besides, HER2 status was not available before 2010 in the SEER database. The number of analyzed patients was very limited when HER2 status is considered, specifically in the propensity score matching analysis. Furthermore, due to the retrospective design of our study, there may be some inherent biases. Finally, agreement on chemotherapy between the SEER database and chart reviews proved to be moderate.[@b29-ott-11-9071] The preferred approach would be to combine data from different sources to obtain more complete information.

Conclusion
==========

Younger patients with high-grade disease tend to have LN metastasis in DCISM. DCISM patients are unlikely to benefit from adjuvant chemotherapy. Further studies and randomized trials should be performed before any appropriate suggestion can be made.
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![DCISM survival outcomes estimated by the Kaplan--Meier method.\
**Notes:** Breast cancer overall survival curves (**A**) and breast cancer-specific survival curves (**B**) for patients with DCISM, stratified by LN status. Breast cancer overall survival (**C**) and breast cancer-specific survival (**D**) stratified by chemotherapy after propensity score matching.\
**Abbreviations:** DCISM, ductal carcinoma in situ with microinvasion; LN, lymph node.](ott-11-9071Fig1){#f1-ott-11-9071}

###### 

Patient characteristics stratified by lymph node status and univariate analysis of risk factors of lymph nodes metastasis

  Variables                       LN positive   \%     LN negative   \%     *P*-value
  ------------------------------- ------------- ------ ------------- ------ -----------
                                                                            
  Age (years)                                                               \<0.001
   \<45                           131           30.1   905           17.4   
   ≥45                            304           69.9   4,288         82.6   
  Ethnicity                                                                 \<0.001
   White                          320           73.6   3,863         74.4   
   Black                          77            17.7   592           11.4   
   Other                          38            8.7    738           14.2   
  Grade                                                                     0.001
   I+II                           158           49.1   2,045         58.5   
   III+IV                         164           50.9   1,448         41.5   
   Unknown                        113                  1,700                
  ER status                                                                 0.396
   Negative                       132           33.8   1,411         31.7   
   Positive                       259           66.2   3,044         68.3   
   Unknown                        44                   738                  
  PR status                                                                 0.414
   Negative                       181           47.3   1,948         45.1   
   Positive                       202           52.7   2,372         54.9   
   Unknown                        52                   873                  
  HER2 status                                                               0.126
   Negative                       54            52.9   693           60.7   
   Positive                       48            47.1   449           39.3   
   Unknown                        333                  4,051                
  Radiotherapy                                                              \<0.001
   No                             282           65.1   2,750         53.2   
   Yes                            151           34.9   2,420         46.8   
   Unknown                        2                    23                   
  Chemotherapy                                                              \<0.001
   No                             130           29.9   4,921         94.8   
   Yes                            305           70.1   272           5.2    
  LN surgery                                                                \<0.001
   SLNB                           121           27.9   3,981         77.1   
   ALND                           313           72.1   1,182         22.9   
   Unknown                        1                    30                   
  Breast surgery                                                            \<0.001
   Lumpectomy                     112           25.7   2,813         54.2   
   Mastectomy                     323           74.3   2,380         45.8   
  Vital status                                                              \<0.001
   Alive                          386           88.7   5,010         96.5   
   Dead of other cause            19            4.4    135           2.6    
   Breast cancer-specific death   30            6.9    48            0.9    

**Abbreviations:** ALND, axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; PR, progesterone receptor; SLNB, sentinel lymph node biopsy.

###### 

Multivariable regression analysis evaluating factors associated with lymph nodes metastasis

  Variables     HR (95% CI)            *P*-value
  ------------- ---------------------- -----------
                                       
  Age (years)                          \<0.001
   \<45         Reference              
   ≥45          0.496 (0.398--0.617)   
  Ethnicity                            0.001
   White        Reference              
   Black        1.547 (1.186--2.018)   
  Grade                                0.008
   I+II         Reference              
   III+IV       1.385 (1.088--1.763)   

###### 

Univariate and multivariate Cox regression analyses for overall and breast cancer-specific survival

  Variables        Overall survival        Breast cancer-specific survival                                                                                                
  ---------------- ----------------------- --------------------------------- ----------------------- --------- ------------------------ --------- ----------------------- ---------
                                                                                                                                                                          
  Age (years)                                                                                                                                                             
   \<45            Reference                                                 Reference                         Reference                          Reference               
   ≥45             1.555 (1.090--2.218)    0.015                             1.762 (1.228--2.529)    0.002     0.534 (0.340--0.838)     0.006     0.763 (0.480--1.215)    0.255
  Ethnicity                                                                                                                                                               
   White           Reference                                                 Reference                         Reference                          Reference               
   Black           2.295 (1.731--3.042)    \<0.001                           2.188 (1.645--2.910)    \<0.001   2.333 (1.346--3.704)     0.006     2.081 (1.243--3.484)    0.005
   Others          0.473 (0.288--0.777)    0.003                             0.474 (0.288--0.780)    0.003     0.892 (0.457--1.743)     0.738     0.911 (0.463--1.793)    0.788
  Grade                                                                                                                                                                   
   I+II            Reference                                                 Reference                         Reference                          Reference               
   III+IV          0.993 (0.742--1.328)    0.960                             0.891 (0.657--1.208)    0.456     2.053 (1.226--3.438)     0.006     1.533 (0.892--2.632)    0.122
   Unknown         1.065 (0.800--1.419)    0.666                             1.042 (0.779--1.395)    0.780     1.461 (0.842--2.537)     0.178     1.369 (0.781--2.401)    0.273
  ER                                                                                                                                                                      
   Negative        Reference                                                 Reference                         Reference                          Reference               
   Positive        0.851 (0.634--1.143)    0.284                             1.314 (0.899--1.921)    0.159     0.666 (0.411--1.080)     0.099     1.386 (0.731--2.627)    0.317
   Unknown         1.118 (0.810--1.542)    0.499                             1.141 (0.562--2.315)    0.716     0.814 (0.468--1.415)     0.466     0.786 (0.254--2.439)    0.677
  PR                                                                                                                                                                      
   Negative        Reference                                                 Reference                         Reference                          Reference               
   Positive        0.646 (0.482--0.867)    0.004                             0.559 (0.385--0.811)    0.002     0.516 (0.311--0.859)     0.011     0.525 (0.272--1.013)    0.055
   Unknown         1.005 (0.753--1.341)    0.972                             0.966 (0.501--1.863)    0.917     0.839 (0.510--1.380)     0.490     1.602 (0.574--4.472)    0.368
  HER2 status                                                                                                                                                             
   Negative        Reference                                                 Reference                         Reference                          Reference               
   Positive        0.661 (0.171--2.557)    0.549                             0.470 (0.119--1.851)    0.280     \<0.001 (0--999)         0.953     \<0.001 (0--999)        0.952
   Unknown         1.296 (0.599--2.801)    0.510                             1.119 (0.512--2.443)    0.779     1.596 (0.382--6.673)     0.522     1.224 (0.279--5.373)    0.789
  LN status                                                                                                                                                               
   N0              Reference                                                 Reference                         Reference                          Reference               
   N1              2.406 (1.676--3.455)    \<0.001                           1.463 (0.926--2.311)    0.103     5.059 (2.973--8.609)     \<0.001   1.480 (0.755--2.903)    0.254
   N2              5.383 (2.929--9.892)    \<0.001                           3.697 (1.818--7.519)    \<0.001   16.798 (8.242--34.237)   \<0.001   4.732 (1.977--11.324)   \<0.001
   N3              8.295 (2.649--25.977)   \<0.001                           6.846 (1.989--23.568)   0.002     20.990 (5.097--86.436)   \<0.001   7.139 (1.449--35.161)   0.016
   Unknown         1.548 (1.095--2.188)    0.013                             0.821 (0.092--7.310)    0.860     1.874 (0.995--3.531)     0.052     1.001 (0.067--14.902)   0.999
  Radiotherapy                                                                                                                                                            
   No              Reference                                                 Reference                         Reference                          Reference               
   Yes             0.585 (0.453--0.754)    \<0.001                           0.597 (0.426--0.837)    0.003     0.440 (0.275--0.702)     0.001     0.625 (0.346--1.129)    0.119
   Unknown         1.119 (0.278--4.510)    0.874                             0.832 (0.203--3.402)    0.798     1.539 (0.213--11.094)    0.669     0.750 (0.097--5.791)    0.782
  Chemotherapy                                                                                                                                                            
   No              Reference                                                 Reference                         Reference                          Reference               
   Yes             2.332 (1.744--3.118)    \<0.001                           1.701 (1.133--2.555)    0.010     6.933 (4.574--10.508)    \<0.001   3.938 (2.168--7.153)    \<0.001
  LN surgery                                                                                                                                                              
   No              Reference                                                 Reference                         Reference                          Reference               
   SLNB            0.585 (0.404--0.848)    0.005                             0.475 (0.051--4.392)    0.511     0.476 (0.237--0.959)     0.038     0.347 (0.021--5.749)    0.460
   ALND            1.004 (0.697--1.448)    0.981                             0.549 (0.059--5.092)    0.598     1.479 (0.769--2.844)     0.241     0.455 (0.027--7.589)    0.584
   Unknown         1.291 (0.461--3.618)    0.627                             1.043 (0.137--7.912)    0.968     2.235 (0.495--10.084)    0.296     1.528 (0.171--13.635)   0.704
  Breast surgery                                                                                                                                                          
   Lumpectomy      Reference                                                 Reference                         Reference                          Reference               
   Mastectomy      1.610 (1.265--2.050)    \<0.001                           1.140 (0.818--1.590)    0.439     3.600 (2.226--5.822)     \<0.001   2.163 (1.182--3.956)    0.012

**Abbreviations:** ALND, axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node; PR, progesterone receptor; SLNB, sentinel lymph node biopsy.

###### 

Baseline characteristics of DCISM patients treated with or without chemotherapy

  Variables        Original, unmatched cohort   *P*-value   Propensity-matched cohort   *P*-value                                       
  ---------------- ---------------------------- ----------- --------------------------- ----------- --------- ----- ------ ----- ------ -------
                                                                                                                                        
  Age (years)                                                                                       \<0.001                             0.450
   \<45            470                          16.8        120                         30.3                  53    22.6   60    25.5   
   ≥45             2\<332                       83.2        276                         69.7                  182   77.4   175   74.5   
  Ethnicity                                                                                         0.469                               0.849
   White           2\<092                       74.7        291                         73.5                  174   74.0   177   75.3   
   Black           331                          11.8        55                          13.9                  30    12.8   26    11.1   
   Other           379                          13.5        50                          12.6                  31    13.2   32    13.6   
  Grade                                                                                             \<0.001                             0.517
   I+II            1\<692                       60.4        169                         42.7                  110   46.8   103   43.8   
   III+IV          1\<110                       39.6        227                         57.3                  125   53.2   132   56.2   
  ER status                                                                                         \<0.001                             0.782
   Negative        799                          28.5        184                         46.5                  110   46.8   113   48.1   
   Positive        2\<003                       71.5        212                         53.5                  125   53.2   122   51.9   
  PR status                                                                                         \<0.001                             0.396
   Negative        1\<188                       42.4        231                         58.3                  137   58.3   146   62.1   
   Positive        1\<614                       57.6        165                         41.7                  98    41.7   89    37.9   
  LN status                                                                                         \<0.001                             0.797
   N0              2\<728                       97.4        188                         47.5                  183   77.9   183   77.9   
   N1              70                           2.5         165                         41.7                  48    20.4   45    19.1   
   N2              4                            0.1         35                          8.8                   4     1.7    6     2.6    
   N3              0                            0           8                           2.0                   0     0      1     0.4    
  Radiotherapy                                                                                      0.035                               0.778
   No              1\<448                       51.7        227                         57.3                  137   58.3   140   59.6   
   Yes             1\<354                       48.3        169                         42.7                  98    41.7   95    40.4   
  LN surgery                                                                                        \<0.001                             0.115
   SLNB            2\<201                       78.6        161                         40.7                  122   51.9   139   59.1   
   ALND            601                          21.4        235                         59.3                  113   48.1   96    40.9   
  Breast surgery                                                                                    \<0.001                             0.578
   Lumpectomy      1\<555                       55.5        139                         35.1                  108   46.0   102   43.4   
   Mastectomy      1\<247                       44.5        257                         64.9                  127   54.0   133   56.6   

**Abbreviations:** ALND, axillary lymph node dissection; DCISM, ductal carcinoma in situ with microinvasion; ER, estrogen receptor; LN, lymph node; PR, progesterone receptor; SLNB, sentinel lymph node biopsy.
